Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-5245a6b0f8b8592e9406a25ffe7ba2b2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-5245a6b0f8b8592e9406a25ffe7ba2b2"/>
<resource>
<Composition>
<id value="composition-en-5245a6b0f8b8592e9406a25ffe7ba2b2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-5245a6b0f8b8592e9406a25ffe7ba2b2"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-5245a6b0f8b8592e9406a25ffe7ba2b2</b></p><a name="composition-en-5245a6b0f8b8592e9406a25ffe7ba2b2"> </a><a name="hccomposition-en-5245a6b0f8b8592e9406a25ffe7ba2b2"> </a><a name="composition-en-5245a6b0f8b8592e9406a25ffe7ba2b2-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1189/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - elmiron</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/17/1189/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp5245a6b0f8b8592e9406a25ffe7ba2b2"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - elmiron"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What elmiron is and what it is used for</li><li>What you need to know before you take elmiron</li><li>How to take elmiron</li><li>Possible side effects</li><li>How to store elmiron</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What elmiron is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What elmiron is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>elmiron is a medicine that contains the active substance pentosan polysulfate sodium. After taking the medicine, it passes into the urine and attaches to the lining of the bladder, helping to form a protective layer.</p><p>elmiron is used in adults to treat bladder pain syndrome characterised by many tiny bleeds or distinctive lesions on the bladder wall and moderate to severe pain and a frequent urge to urinate.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take elmiron"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take elmiron"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take elmiron if you are</p><ul><li>allergic to pentosan polysulfate sodium or any of the other ingredients of this medicine (listed in section 6)</li><li>bleeding (other than menstrual bleeding)</li></ul><p>Warnings and precautions<br/>Talk to your doctor or pharmacist before taking elmiron if you have:</p><ul><li>to undergo surgery</li><li>a blood clotting disorder or increased risks of bleeding, such as using a medicine that inhibits blood clotting</li><li>ever had a reduced number of blood platelets caused by the medicine called heparin</li><li>reduced liver or kidney function</li></ul><p>Rare cases of retinal disorders (pigmentary maculopathy) have been reported with use of elmiron (especially after long term use). Tell your doctor immediately if you experience visual changes such as difficulty when reading, visual distortions, altered colour vision and/or slower adjustment to low or reduced light. Your doctor will discuss with you whether the treatment should be continued. For early detection of retinal disorders, eye examination will be performed regularly.</p><p>Children and adolescents elmiron is not recommended in children under 18 years as safety and efficacy have not been established in this group.</p><p>Other medicines and elmiron Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Inform your doctor or pharmacist, particularly if you use medicines that prevent blood clotting, or painkillers that reduce blood clotting.</p><p>Pregnancy and breast-feeding elmiron is not recommended during pregnancy or breast-feeding.</p><p>Driving and using machines elmiron has no or negligible influence on the ability to drive and use machines.</p><p>elmiron contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take elmiron"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take elmiron"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is: 1 capsule, 3 times daily Your doctor will assess your response to elmiron every 6 months.</p><p>Method of use Take the capsules whole with one glass of water, at least 1 hour before or 2 hours after meals.</p><p>If you take more elmiron than you should Inform your doctor in case of overdose. Stop taking elmiron if side effects occur until they disappear.</p><p>If you forget to take elmiron Do not take a double dose to make up for a forgotten capsule.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Side effects have been observed with the following frequencies: Common: may affect up to 1 in 10 people</p><ul><li>infections, flu</li><li>headache, back pain</li><li>dizziness</li><li>nausea, indigestion, diarrhoea, abdominal pain, abdomen enlarged</li><li>rectal bleeding</li><li>accumulation of fluid in arms or legs</li><li>hair loss</li><li>weakness, pelvic (lower abdomen) pain</li><li>need to urinate more frequently than usual</li><li>abnormal liver function</li></ul><p>Uncommon: may affect up to 1 in 100 people</p><ul><li>lack of blood platelets, red or white blood cells</li><li>bleeding, including small bleeding beneath the skin</li><li>allergic reactions, increased sensitivity to light</li><li>loss of appetite, weight gain or loss</li><li>severe mood swings or depression</li><li>increased sweating, sleeplessness</li><li>restlessness</li><li>abnormal sensation such as prickling, tingling and itchiness</li><li>flow of tears, lazy eye</li><li>ringing or buzzing in the ears</li><li>breathing difficulties</li><li>indigestion, vomiting, wind, difficulty passing stools</li><li>mouth ulcer</li><li>skin rash, increased mole size</li><li>joint or muscle pain</li></ul><p>Not known: frequency cannot be estimated from the available data</p><ul><li>blood clotting disorders</li><li>allergic reactions</li><li>abnormal liver function</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store elmiron"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store elmiron"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><ul><li>bottle Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</li></ul><p>Keep the bottle tightly closed in order to protect from moisture. After first opening: use within 45 days. Dispose any remaining capsules after this period.</p><ul><li>blister Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</li></ul><p>Do not store above 30 C.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What elmiron contains</p><ul><li>The active substance is pentosan polysulfate sodium. One capsule contains 100 mg pentosan polysulfate sodium.</li><li>The other ingredients are:</li></ul><p>Capsule content: microcrystalline cellulose, magnesium stearate</p><p>Capsule shell: gelatin, titanium dioxide (E171)</p><p>What elmiron looks like and contents of the pack The capsules are white and non-transparent, provided in a plastic bottle with child resistant closure or plastic/aluminium blisters, packed in a carton.</p><ul><li><p>bottle Each carton contains 90 capsules or 300 (3 bottles x 100) capsules.</p></li><li><p>blister Each carton contains 90 capsules.</p></li></ul><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer</p><p>bene-Arzneimittel GmbH Herterichstrasse 1-3 D-81479 Munich tel: +49 (0)89 749fax: +49 (0)89 74987e-mail: <a href="mailto:contact@bene-arzneimittel.de">contact@bene-arzneimittel.de</a></p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>BG, CZ, EE, EL, IS, IT, CY, LV, MT, PT, RO, SK bene-Arzneimittel GmbH, D-81479 Munich, / N mecko / Saksamaa / / Germany / skaland / Germania / V cija / Il- ermanja / Alemanha / Nemecko, Tel / Te . / / S mi / Tel.: +49 (0)89 749870, <a href="mailto:contact@bene-arzneimittel.de">contact@bene-arzneimittel.de</a></p><p>AT SIGMAPHARM Arzneimittel GmbH, Leystra e 129, A-1200 Wien, sterreich, Tel.: +43 (0) 1 330 06 71-0, <a href="mailto:mail@sigmapharm.at">mail@sigmapharm.at</a></p><p>BE, LU, NL Pharmanovia Benelux B.V., Burgemeester Gulj laan 2, NL-4837 CZ Breda, Pays-Bas, Nederland, Niederlande, T l/Tel: +31 (0)76 5600030, <a href="mailto:info.benelux@pharmanovia.com">info.benelux@pharmanovia.com</a></p><p>DE<br/>Dr. Pfleger Arzneimittel GmbH, D-96045 Bamberg,<br/>Deutschland,<br/>Tel.: +49 (0)951 6043-0, <a href="mailto:info@dr-pfleger.de">info@dr-pfleger.de</a></p><p>DK, NO Navamedic AB, G teborgsv gen 74, S-433 63 S vedalen, Sverige, Tlf: +46 (0)31 3351190, <a href="mailto:infose@navamedic.com">infose@navamedic.com</a></p><p>ES Lacer S.A., Sardenya 350, 08025 Barcelona, Espa a, Tel: +34 (0)934465300, <a href="mailto:infog@lacer.es">infog@lacer.es</a></p><p>FI, SE Navamedic AB, G teborgsv gen 74, S-433 63 S vedalen, Ruotsi/Sverige, Puh/Tel: +46 (0)31 3351190, <a href="mailto:infose@navamedic.com">infose@navamedic.com</a></p><p>FR Inresa SAS, 1 rue Jean Monnet, F-68870 Bartenheim, France, T l: +33 (0)389 707660, <a href="mailto:info@inresa.fr">info@inresa.fr</a></p><p>HR<br/>MEDICOPHARMACIA d.o.o., Pere Budmanija 5, 10000 Zagreb, Hrvatska, Tel: + 385 1 55 84 HU K ri Pharma Hungary Kft., 4032 Debrecen, Bartha B. u. 7,<br/>Magyarorsz g, Tel.: +36 52 431 IE Consilient Health, Block 2A Richview Office Park, Clonskeagh, Dublin 14, D14 Y0A5 Ireland, Tel: +353 (0) 1 2057760, <a href="mailto:irishoffice@consilienthealth.com">irishoffice@consilienthealth.com</a></p><p>LT UAB Norameda, Meistr g. 8A, LT-02189 Vilnius, Lietuva, Tel. +370 5 2306PL Norameda Polska Sp. z o.o., Kili skiego 20, PL-05-500 Piaseczno, Polska, Tel.: +48 (0) 504 278 778, <a href="mailto:kontakt.pl@norameda.com">kontakt.pl@norameda.com</a></p><p>SI Lenis d.o.o., Litostrojska cesta 52, 1000 Ljubljana, Slovenija, Tel: +386(0) 1 235 07 00, <a href="mailto:info@lenis.si">info@lenis.si</a></p><p>XI Consilient Health Limited Tel: +353 (0)1 205 7This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency website <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp5245a6b0f8b8592e9406a25ffe7ba2b2"/>
<resource>
<MedicinalProductDefinition>
<id value="mp5245a6b0f8b8592e9406a25ffe7ba2b2"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp5245a6b0f8b8592e9406a25ffe7ba2b2"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp5245a6b0f8b8592e9406a25ffe7ba2b2</b></p><a name="mp5245a6b0f8b8592e9406a25ffe7ba2b2"> </a><a name="hcmp5245a6b0f8b8592e9406a25ffe7ba2b2"> </a><a name="mp5245a6b0f8b8592e9406a25ffe7ba2b2-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1189/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: elmiron 100 mg capsules, hard</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/17/1189/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="elmiron 100 mg capsules, hard"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
